We found that breast tumor cells treated with EZH2 small-molecule inhibitors altered the secretome of inflammatory mediators, thus stimulating TAMs infiltration and polarization to a tumor-promoting phenotype, whereas EZH2 genetical deletion rendered the opposite effect. The gene discussed is EZH2; the disease is neoplasm.